Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. 2014

Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
Unit of Infectious Diseases, Hospital Universitario "12 de Octubre". Instituto de Investigación Hospital "12 de Octubre" (i+12). School of Medicine, Universidad Complutense, Madrid, Spain.

Serial monitoring of peripheral blood lymphocyte subpopulations (PBLSs) counts might be useful in predicting post-transplant opportunistic infection (OI) after kidney transplantation (KT). PBLSs were prospectively measured in 304 KT recipients at baseline and post-transplant months 1 and 6. Areas under receiver operating characteristic curves were used to evaluate the accuracy of different subpopulations in predicting the occurrence of overall OI and, specifically, cytomegalovirus (CMV) disease. We separately analyzed patients not receiving (n = 164) or receiving (n = 140) antithymocyte globulin (ATG) as induction therapy. In the non-ATG group, a CD8(+) T-cell count at month 1 <0.100 × 10(3) cells/μl had negative predictive values of 0.84 and 0.86 for the subsequent occurrence of overall OI and CMV disease, respectively. In the multivariate Cox model, a CD8(+) T-cell count <0.100 × 10(3) cells/μl was an independent risk factor for OI (adjusted hazard ratio: 3.55; P-value = 0.002). In the ATG group, a CD4(+) T-cell count at month 1 <0.050 × 10(3) cells/μl showed negative predictive values of 0.92 for the subsequent occurrence of overall OI and CMV disease. PBLSs monitoring effectively identify KT recipients at low risk of OI, providing an opportunity for individualizing post-transplant prophylaxis practices.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000961 Antilymphocyte Serum Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION. ATGAM,Antilymphoblast Globulins,Antilymphocyte Antibodies,Antilymphocyte Globulin,Lymphocytotoxic Antibodies,Anti-Thymocyte Globulin,Antilymphocyte Immunoglobulin,Antithymocyte Globulin,Antithymoglobulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine),Pressimmune,Anti Thymocyte Globulin,Anti-Thymocyte Globulins,Antibodies, Antilymphocyte,Antibodies, Lymphocytotoxic,Antibody, Antilymphocyte,Antibody, Lymphocytotoxic,Antilymphoblast Globulin,Antilymphocyte Antibody,Antilymphocyte Globulins,Antilymphocyte Immunoglobulins,Antilymphocyte Serums,Antithymocyte Globulins,Antithymoglobulins,Globulin, Anti-Thymocyte,Globulin, Antilymphoblast,Globulin, Antilymphocyte,Globulin, Antithymocyte,Globulins, Anti-Thymocyte,Globulins, Antilymphoblast,Globulins, Antilymphocyte,Globulins, Antithymocyte,Immunoglobulin, Antilymphocyte,Immunoglobulins, Antilymphocyte,Lymphocyte Immune Globulin, Anti Thymocyte Globulin,Lymphocytotoxic Antibody,Serum, Antilymphocyte,Serums, Antilymphocyte
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
December 1992, Transplantation proceedings,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
January 1987, Bollettino dell'Istituto sieroterapico milanese,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
April 1975, Cellular immunology,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
January 1999, Folia microbiologica,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
June 2023, Transplant immunology,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
December 1989, Der Internist,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
March 2018, Cytometry. Part B, Clinical cytometry,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
March 2001, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
January 1979, Advances in experimental medicine and biology,
Mario Fernández-Ruiz, and Francisco López-Medrano, and Luis M Allende, and Amado Andrés, and Ana García-Reyne, and Carlos Lumbreras, and Rafael San-Juan, and José M Morales, and Estela Paz-Artal, and José M Aguado
January 1976, Bollettino dell'Istituto sieroterapico milanese,
Copied contents to your clipboard!